Endocrine最新文献

{"title":"Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews.","authors":"Xiaoye Hu, Yongsheng Wang, Kehu Yang, Xiuxia Li","doi":"10.1007/s12020-025-04179-x","DOIUrl":"10.1007/s12020-025-04179-x","url":null,"abstract":"<p><strong>Objective: </strong>Summarize the effectiveness and safety of Semaglutide for non-diabetic obese patients through umbrella analysis.</p><p><strong>Methods: </strong>From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity. AMSTAR-2 assessed review quality, ROB scrutinized RCT quality, and RCTs were selected based on overlap. Random-effects meta-analysis synthesized data on weight, waist, BMI, ect.</p><p><strong>Results: </strong>The study encompassed 7 reviews and 10 RCTs, revealing that semaglutide induced average weight loss 11.71 kg [-13.16, -10.26] in non-diabetic obese patients, a 12.79% reduction [-14.4, -11.18]. Notably, ≥5, ≥10, ≥15, and ≥20% weight-loss rates significantly increased. Semaglutide also reduced waist by 9.39 cm [-10, -8.79], BMI by 4.27 kg/m^2 [-4.78, -3.75], SBP by 4.78 mmHg [-5.63, -3.93], DBP by 2.56 mmHg [-3.96, -1.17], and lipids by 3.2 mmol/l [-5.65, -0.75]. FBG significantly dropped by 5.46 mmol/l [-8.99, -1.93], and SF-36 scores improved by 1.7 points [0.78, 2.63]. However, common adverse reactions included nausea [RR: 2.59], diarrhea [RR: 1.77], and constipation [RR: 2.07].</p><p><strong>Conclusions: </strong>Semaglutide shows significant weight loss and health benefits in non-diabetic obesity. However, Recent studies show semaglutide can cause NAION and erectile dysfunction, beyond previously reported adverse reactions. Besides, High overlap in current research highlights a lack of RCTs. And there is a high degree of heterogeneity across included studies. More large-scale, rigorous RCTs are needed to assess safety and support clinical use.</p><p><strong>Register: </strong>The study was registered at PROSPERO on 24 December 2023 (registration number:CRD42023493235).</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"387-397"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant radiation therapy improves outcome of patients with surgical resected adrenocortical carcinoma.","authors":"Shuqing Ma, Luming Wu, Lei Ye, Mouhammed Amir Habra, Vania Balderrama-Brondani, Weiqing Wang","doi":"10.1007/s12020-025-04163-5","DOIUrl":"10.1007/s12020-025-04163-5","url":null,"abstract":"<p><strong>Purpose: </strong>Adrenocortical carcinoma (ACC) is a rare malignancy known for high rates of recurrence and poor prognosis. Previous studies revealed controversial roles of adjuvant radiation therapy (RT) in patient management. This study aimed to investigate the role of adjuvant RT in postoperative ACC patients.</p><p><strong>Methods: </strong>Patients with histologically confirmed ACC who underwent surgical resection in the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2020 were enrolled. Propensity score matching (PSM) was used to balance baseline characteristics between patients receiving adjuvant RT and patients who did not receive RT. Overall survival (OS) and recurrence-free survival (RFS) was analyzed using the Kaplan-Meir method. Risk factors associated with survival outcome was analyzed by univariate and multivariate Cox regression analyses. Subgroup analyses were stratified by European Network for the Study of Adrenal Tumors (ENSAT) disease stage or chemotherapy. A joint retrospective analysis of stage III patients was performed based on data obtained from Ruijin Hospital and MD Anderson Cancer Center.</p><p><strong>Results: </strong>Among the 700 patients enrolled, 137 patients undergoing postoperative RT were matched with 137 patients who did not receive RT. Overall survival for patients with adjuvant RT was better than patients without RT (log-rank P = 0.015). The 3-year and 5-year OS were 55.2 and 47.1% for patients with RT, vs 42.6 and 34.0% for patients without RT. Multivariate analysis showed adjuvant RT was independently associated with lower mortality (hazard ratio [HR] 0.63, P = 0.007). Subgroup analysis stratified by disease stage demonstrated that adjuvant RT showed the most favorable effect in stage III patients (HR 0.53, P = 0.013). Furthermore, joint analysis of two centers showed a tendency of better OS and local control rate for stage III patients with mitotane plus RT than those with mitotane alone.</p><p><strong>Conclusion: </strong>Our study indicated that adjuvant RT was associated with improved prognosis for ACC patients, especially for patients with ENSAT stage III diseases. Integrating adjuvant RT into standard care of ACC may be considered.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"597-606"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143042976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pros and cons of surgical versus conservative management for head and neck paraganglioma: a real-world data analysis.","authors":"L Canu, L Zanatta, C Sparano, R Santoro, G Mannelli, S Zamengo, B Jance, F Amore, T Ercolino, M Mannelli, M Maggi, E Rapizzi","doi":"10.1007/s12020-025-04167-1","DOIUrl":"10.1007/s12020-025-04167-1","url":null,"abstract":"<p><strong>Purpose: </strong>To compare functional deficits associated to surgery with those caused by the growth of the head and neck paragangliomas (HNPGLs).</p><p><strong>Methods: </strong>72 patients with HNPGLs were included. Patients were divided in group A (49 patients undergoing surgery) and group B (23 patients following a wait and see approach). Each patient was subjected to clinical evaluation and genetic testing. The presence of functional neurological deficits in speech or swallowing and quality of life were assessed via a dedicated otolaryngologist visit, three posted questionnaires (VHI, DHI, and MDADI), and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35.</p><p><strong>Results: </strong>Thirty-four patients from group A (69.4%) and 18 from group B (78.2%) agreed to fill out the posted questionnaires. Eighteen patients from group A (36.7%) and 10 from group B (43.5%) underwent a dedicated otolaryngologist visit. A significant difference between group A and B was observed in the VHI (p = 0.001) and DHI scoring (p = 0.020), and at the otolaryngologist visit (mild neurological disabilities, p = 0.007). Patients with familial forms presented multiple HNPGLs (p = 0.011), multiple secreting lesions (p = 0.010) and underwent surgery more times for HNPGLs (p = 0.009) and for both HNPGLs and sympathetic PGLs (p = 0.015). ROC curve analysis suggests that surgery in carotid body tumors >34 mm may be more frequently associated with nerve injury.</p><p><strong>Conclusion: </strong>The management of HNPGL patients remains challenging for clinicians. This preliminary study seems to suggest that surgery still represents the first choice for patients with small lesions. An accurate clinical evaluation is mandatory to avoid non-resolving surgery and possible neurovascular long-term complications.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"607-615"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143042978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should adrenal incidentaloma patients be evaluated for muscle mass, function, and quality? A cross-sectional study.","authors":"Samet Alkan, Sedat Can Guney, Can Akcura, Nilufer Ozdemir, Zeliha Hekimsoy","doi":"10.1007/s12020-025-04170-6","DOIUrl":"10.1007/s12020-025-04170-6","url":null,"abstract":"<p><strong>Purpose: </strong>Our study evaluated skeletal muscle mass, function and quality among mild autonomous cortisol secretion (MACS) patients and non-functioning adrenal incidentaloma (NFAI) patients in comparison with the control group without adrenal mass.</p><p><strong>Methods: </strong>63 NFAI (49 female, 14 male) and 31 MACS (24 female, 7 male) patients were included in the study. As the control group, 44 patients (31 women, 13 men) who were known to have no radiological adrenal pathology on computed tomography or magnetic resonance imaging performed for other reasons were selected. After recording the laboratory parameters of the patients, anthropometric measurements, handgrip strength test with dynamometer, SARC-F survey and bioelectrical impedance analysis (BIA) measurements were performed.</p><p><strong>Results: </strong>There was no statistical difference among the groups in terms of age, gender, and BMI parameters. Handgrip strength (HGS), skeletal muscle mass (SMM) index (SMM/BMI), and skeletal muscle quality (HGS/SMM), values used to evaluate muscle strength and quality, were found to be significantly lower in both the MACS and NFAI groups compared to the control group (p = 0.004, p = 0.012 and p = 0.034 respectively). This significance was also present in women subgroup analyses (p = 0.002, p = 0.037 and p = 0.039 respectively), but these parameters lost their statistical significance in men. In the correlation analysis of the female subgroup, 24-h free urine cortisol value was inversely proportional to skeletal muscle quality (r_s = -0.417, p = 0.008).</p><p><strong>Conclusion: </strong>Our study showed that there is a decrease in muscle mass and function in female AI patients, and this decrease is more severe in MACS patients. These results may suggest that mild cortisol excess also has negative effects on skeletal muscle metabolism.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"616-626"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143042980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The monocyte/HDLc ratio and LDLc are two independent predictors of the response of Graves' ophthalmopathy patients to parenteral glucocorticoids.","authors":"Rosario Le Moli, Adriano Naselli, Tommaso Piticchio, Andrea Tumminia, Francesco Pallotti, Antonino Belfiore, Francesco Frasca","doi":"10.1007/s12020-025-04185-z","DOIUrl":"10.1007/s12020-025-04185-z","url":null,"abstract":"<p><strong>Purpose: </strong>Graves' ophthalmopathy (GO) is an inflammatory-autoimmune disease and parenteral glucocorticoids (IvGCs) are the first-line therapy in the moderate to severe forms. Oxidative stress (OX) and cholesterol have been related to severe forms and to the clinical outcome of GO. Recently some new biomarkers have been proposed as predictors of the clinical outcome in some cardiovascular and autoimmune diseases. We hypothesized that the monocyte-to-high-density lipoprotein cholesterol (HDL) ratio (MHR) could be a useful biomarker in GO management and aimed to evaluate the possible role of the MHR as a predictor of the clinical outcome in patients with active, moderate to severe GO treated with IvGCs.</p><p><strong>Methods: </strong>We retrospectively studied 115 patients, 86 females and 29 males, with active, moderate to severe GO who were treated with IvGCs for 12 weeks at our institution. GO severity was evaluated according to EUGOGO suggestions, GO clinical activity and the clinical outcome of GO to IvGCs were evaluated by the seven-point Clinical Activity Score (CAS).</p><p><strong>Results: </strong>The baseline low density lipoproteins cholesterol (LDLc) and MHR were negatively and independently related to the improvement of GO at 12 weeks (p = 0.024 and p = 0.012, respectively). The value of the MHR = 0.0095 was identified as the best cut off by ROC curve and appeared to be a potentially useful tool to help identify patients with a poor response to IvGCs.</p><p><strong>Conclusions: </strong>The MHR might be an useful tool to manage the immunosuppressant therapy in GO patients; our study confirms the role of LDLc as a predictor of GO outcome after IvGCs treatment.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":"545-552"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision treatment guided by patient-derived organoids-based drug testing for locally advanced thyroid cancer: a single arm, phase 2 study.","authors":"Ziliang Guo, Jiaye Liu, Xinyue Zhang, Yu Ma, Yichao Wang, Peng Li, Rui Huang, Zhihui Li","doi":"10.1007/s12020-025-04240-9","DOIUrl":"https://doi.org/10.1007/s12020-025-04240-9","url":null,"abstract":"<p><strong>Purpose: </strong>Locally advanced thyroid cancer (LATC) presents significant surgical challenges, with a high risk of incomplete resection and poor prognosis. Patient-derived organoids (PDOs) are a powerful tool to assess drug sensitivity at an individual level and to suggest new treatment options or re-challenge. This study aimed to evaluate the method's feasibility and efficacy as applied to patients with LATC.</p><p><strong>Methods: </strong>In this single arm, phase 2 study, we enrolled 75 patients with LATC. Biopsies from the primary tumor or metastatic site were cultured using organoid models. Sensitivity testing was performed by using PDOs with a panel of drugs with proven activity in phase II or III trials. At the discretion of the investigator considering toxicity, the drug with the highest relative activity was offered. The primary endpoint was the objective response rate (ORR).</p><p><strong>Results: </strong>Fifty-five patients received at least one dose of recommended drug and the primary endpoint, objective response was met in 18 patients with an overall ORR as 32.7% (95% CI 20.7-46.7). Based on the pre-defined subgroups of different histological subtypes, the ORR for patients with differentiated thyroid cancer, medullary thyroid cancer, anaplastic thyroid cancer were 32.6%, (95% CI 19.1-48.5), 16.7% (95% CI 0.4-64.1) and 50% (95% CI 11.8-88.2), respectively. The R0/R1 resection rate was 34.5% (19/55).</p><p><strong>Conclusions: </strong>This study is the first to validate the feasibility of PDOs and in vitro sensitivity testing for LATC. PDO-based neoadjuvant therapy holds promise in improving prognosis and providing surgical opportunities for these patients.</p><p><strong>Trial registration: </strong>The study was registered at ClinicalTrials.gov (NCT06482086) on 06/25/2024.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal associations between congenital adrenal hyperplasia and neuropsychiatric conditions- a Mendelian Randomization Study.","authors":"Yang Liu, Xiaokun Gang, Yuan Gao, Guixia Wang","doi":"10.1007/s12020-025-04237-4","DOIUrl":"https://doi.org/10.1007/s12020-025-04237-4","url":null,"abstract":"<p><strong>Background: </strong>Congenital adrenal hyperplasia (CAH), predominantly caused by 21-hydroxylase deficiency (21-OHD) due to CYP21A2 mutations, disrupts cortisol synthesis and adrenal androgen homeostasis. Observational studies suggest CAH patients exhibit elevated risks of neuropsychiatric disorders, but causal mechanisms remain unestablished. We hypothesized that reduced CYP21A2 expression, reflecting CAH, differentially influences psychiatric outcomes via tissue-specific pathways.</p><p><strong>Methods: </strong>Using two-sample Mendelian randomization (MR), we analyzed tissue-specific CYP21A2 expression quantitative trait loci (eQTLs) from adrenal (GTEx v8) and whole blood (GTEx v8 and eQTLGen meta-analysis). Genetic instruments were validated via positive control MR with classical CAH biomarkers. Associations with ten neuropsychiatric disorders were assessed using inverse-variance-weighted MR, supplemented by sensitivity analyses (LCV, SMR) and LD score regression.</p><p><strong>Results: </strong>Adrenal-derived CYP21A2 downregulation reduced Alzheimer's disease (AD) risk (discovery: OR = 1.245, replication: OR = 1.100) but increased autism spectrum disorder (ASD) susceptibility (discovery: OR = 0.766, replication: OR = 0.659). Conversely, blood-derived eQTLs showed opposing effects that decreased ASD risk (discovery: OR = 1.072, replication: OR = 1.071) and elevated AD risk (OR = 0.968 for both discovery and replication). Both tissues linked reduced CYP21A2 expression to elevated bioavailable testosterone (adrenal: OR = 0.972, p = 0.04; blood: OR = 0.983, p = 0.01), consistent with CAH pathophysiology.</p><p><strong>Conclusion: </strong>Our research indicates that adrenal-driven pathways of CYP21A2 deficiency may reduce the risk of AD while increasing the ASD risk. These findings underscore the pivotal role of endocrine mechanisms in the pathogenesis of neuropsychiatric disorders and advocate for personalized CAH management integrating mental health monitoring.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fixed-ratio combination of GLP-1 receptor agonist and basal insulin: simplifying type 2 diabetes treatment.","authors":"Miriam Longo, Maria Ida Maiorino, Dario Giugliano, Filip K Knop, Katherine Esposito","doi":"10.1007/s12020-025-04243-6","DOIUrl":"https://doi.org/10.1007/s12020-025-04243-6","url":null,"abstract":"","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144028121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The additive value of real-time elastography to thyroid ultrasound in detecting papillary carcinoma in nodules over 20 mm in diameter.","authors":"Nikolaos Angelopoulos, Dimitrios G Goulis, Ioannis Chrisogonidis, Sarantis Livadas, Rodis D Paparodis, Ioannis Androulakis, Juan Carlos Jaume, Ioannis Iakovou","doi":"10.1007/s12020-025-04248-1","DOIUrl":"https://doi.org/10.1007/s12020-025-04248-1","url":null,"abstract":"<p><strong>Purpose: </strong>Ultrasonography (US) is the most accurate and cost-effective imaging method for identifying thyroid nodules. The difficulty in determining which nodules to sample for fine-needle aspiration (FNA) cytology has prompted the introduction of the Thyroid Imaging Reporting and Data Systems (TIRADS), which assesses the malignancy risk associated with thyroid nodules. Real-time elastography (RTE), coupled with strain ratio (SR) measurements, offers a means to evaluate the nodule stiffness and potentially discern their likelihood of being malignant. The present study aimed to investigate the efficacy of RTE and SR, combined with the TIRADS grading systems, in distinguishing between benign and malignant thyroid nodules.</p><p><strong>Methods: </strong>From 1094 patients with thyroid nodules referred for thyroid ultrasound at a University Hospital, those with thyroid nodules ≥20 mm in diameter were enrolled. Each nodule was categorized according to European (EU)- and American College of Radiology (ACR)-TIRADS systems, ranging from 2-5. Nodules' SRs were evaluated together with RTE. The thyroid nodule diagnosis was documented by post-thyroidectomy histopathological examination and/or US-guided FNA according to the Bethesda classification of the examined smears.</p><p><strong>Results: </strong>The study involved 267 patients (mean age 60.3 ± 14.3 years; 46 males and 221 females) with 308 nodules categorized into EU-TIRADS categories 3, 4, and 5. Of these nodules, 22 proved malignant, and 286 benign. The elastography ratio exhibited high predictive performance in diagnosing thyroid malignancy (p < 0.001) at a threshold value of >0.84 (sensitivity 90.9%, specificity 73.4%). In the 168 nodules with EU-TIRADS 3, this threshold had 100% sensitivity and 75.1% specificity in discriminating malignant thyroid nodules.</p><p><strong>Conclusion: </strong>Combining TIRADS with data derived from RTE reduces unnecessary FNAs and surgeries in patients with thyroid nodular disease.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of delayed surgery in differentiated thyroid carcinoma and medullary thyroid carcinoma.","authors":"Maomi Song","doi":"10.1007/s12020-025-04241-8","DOIUrl":"https://doi.org/10.1007/s12020-025-04241-8","url":null,"abstract":"<p><strong>Background: </strong>Delay in surgery and the impact on survival in thyroid cancer is unclear. We sought to investigate the association between time to surgery and survival in patients with differentiated thyroid carcinoma (DTC) or medullary thyroid carcinoma (MTC).</p><p><strong>Methods: </strong>In this retrospective study, we included patients who were diagnosed with DTC(including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC) and oncocytic thyroid carcinoma (OTC)) or MTC between 2000 and 2021. Data was gathered from the Surveillance, Epidemiology and End Results (SEER) database. And we defined the cutoff period for delayed surgery of DTC was 3 months, while 2 months for MTC. Kaplan-Meier method and log-rank test were used to analyze overall survival (OS) and cancer-specific survival (CSS).</p><p><strong>Results: </strong>181588 patients were included in our study. Of which 165,202 (91.0%) were diagnosed with PTC, 9525 (5.2%) were FTC, 4128 (2.3%) were OTC and 2733 (1.5%) were MTC. Comparison of clinical paraments between delayed and non-delayed patients of the four types of thyroid cancer indicated that delayed surgery may alter the clinical characteristics, leading to tumor progression or increased aggressiveness, especially for lymph node metastasis. Meanwhile, delayed surgery (≥3 months) was associated with decreased survival in PTC and FTC, not for OTC. For MTC, delayed surgery (≥2 months) was associated with poorer OS. Additionally, we analyzed the trends in delayed surgery and found that except for an upward trend in PTC, other pathological types showed no significant fluctuations.</p><p><strong>Conclusions: </strong>Delaying surgery for DTC and MTC should be avoided, as this could lead to tumor progression or more aggressive behavior and poorer prognosis.</p>","PeriodicalId":49211,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}